Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report

BRAF fusions are rare driver oncogenes in non-small cell lung cancer (NSCLC). Similar with BRAF V600E mutation, it could also activate the MAPK signaling pathway. There are a few case reports which had indicated the potential response to BRAF inhibitors and its important role as de novo driver mutat...

Full description

Bibliographic Details
Main Authors: Yun-Tse Chou, Chien-Chung Lin, Chung-Ta Lee, Dean C. Pavlick, Po-Lan Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
BRAF fusion
MET amplification
case report
double driver mutation
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.838798/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.838798/full

Similar Items